Imatinib Sandoz (Imatinib)

Imatinib acts on malignant cells driven by specific tyrosine kinase pathways and is indicated for several hematologic and solid tumours.

• Chronic myeloid leukemia (CML): suppresses the BCR‑ABL driven leukemic clone, leading to hematologic and cytogenetic remission.
• Gastrointestinal stromal tumor (GIST): inhibits c‑KIT and PDGFR signaling, reducing tumor growth and disease progression.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): provides targeted inhibition of BCR‑ABL, contributing to remission when combined with chemotherapy.

• Imatinib binds competitively to the ATP‑binding site of BCR‑ABL, c‑KIT and platelet‑derived growth factor receptors (PDGFR), preventing phosphorylation and downstream signaling that drive cell proliferation and survival. By blocking these tyrosine kinases, the drug induces apoptosis and halts the expansion of malignant clones in affected tissues. The inhibition is dose‑dependent and results in reduced angiogenesis and impaired tumor microenvironment interactions, contributing to clinical efficacy across multiple tumor types.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the lower extremities.
• Fatigue: generalized tiredness affecting daily activities.
• Diarrhea: loose stools that may require fluid replacement.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiotoxicity: congestive heart failure or reduced left‑ventricular function.
• Severe neutropenia: marked decrease in neutrophil count increasing infection risk.
• Pulmonary hypertension: increased pressure in pulmonary arteries, potentially life‑threatening.

When prescribing Imatinib, clinicians should consider several safety and monitoring measures.

• Baseline assessment: obtain complete blood count, liver function tests and cardiac evaluation before initiating therapy.
• Monitoring: perform regular CBC, hepatic panel and ECG to detect hematologic or cardiac toxicity.
• Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers that may alter plasma levels.
• Pregnancy: avoid use during pregnancy; discuss risks and alternative options with women of childbearing potential.
• Breastfeeding: contraindicated; advise against nursing while on treatment.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Imatinib interacts with several medicines that can modify its effectiveness or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Imatinib exposure and toxicity.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug levels, compromising efficacy.
• Antacids containing aluminum or magnesium: can decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Proton pump inhibitors: may modestly reduce bioavailability; separate dosing by at least 2 hours.
• Warfarin: potential for altered anticoagulant effect; monitor INR closely.
• Digoxin: possible increase in serum concentration; assess cardiac function.